CONAVI MEDICAL CORP (CNVI.CA) Fundamental Analysis & Valuation
TSX-V:CNVI • CA2059531020
Current stock price
0.39 CAD
0 (0%)
Last:
This CNVI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CNVI.CA Profitability Analysis
1.1 Basic Checks
- In the past year CNVI has reported negative net income.
- In the past year CNVI has reported a negative cash flow from operations.
- In the past 5 years CNVI reported 4 times negative net income.
- In the past 5 years CNVI reported 4 times negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -164.51%, CNVI perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.51% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CNVI's Gross Margin of 107.51% is amongst the best of the industry. CNVI outperforms 100.00% of its industry peers.
- CNVI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 107.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CNVI.CA Health Analysis
2.1 Basic Checks
- CNVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- There is no outstanding debt for CNVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -29.67, we must say that CNVI is in the distress zone and has some risk of bankruptcy.
- CNVI's Altman-Z score of -29.67 is in line compared to the rest of the industry. CNVI outperforms 46.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -29.67 |
ROIC/WACCN/A
WACC7.98%
2.3 Liquidity
- CNVI has a Current Ratio of 0.60. This is a bad value and indicates that CNVI is not financially healthy enough and could expect problems in meeting its short term obligations.
- CNVI has a Current ratio (0.60) which is in line with its industry peers.
- CNVI has a Quick Ratio of 0.60. This is a bad value and indicates that CNVI is not financially healthy enough and could expect problems in meeting its short term obligations.
- CNVI's Quick ratio of 0.60 is in line compared to the rest of the industry. CNVI outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 |
3. CNVI.CA Growth Analysis
3.1 Past
- CNVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.95%, which is quite impressive.
- CNVI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -91.82%.
- CNVI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.88% yearly.
EPS 1Y (TTM)76.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.93%
Revenue 1Y (TTM)-91.82%
Revenue growth 3Y-30.88%
Revenue growth 5YN/A
Sales Q2Q%-97.48%
3.2 Future
- CNVI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.03% yearly.
- Based on estimates for the next years, CNVI will show a very strong growth in Revenue. The Revenue will grow by 60.40% on average per year.
EPS Next Y50%
EPS Next 2Y25.5%
EPS Next 3Y17.86%
EPS Next 5Y17.03%
Revenue Next Year-34.34%
Revenue Next 2Y17.31%
Revenue Next 3Y44.8%
Revenue Next 5Y60.4%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. CNVI.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CNVI. In the last year negative earnings were reported.
- Also next year CNVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CNVI's earnings are expected to grow with 17.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.5%
EPS Next 3Y17.86%
5. CNVI.CA Dividend Analysis
5.1 Amount
- CNVI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CNVI.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:CNVI (4/30/2026, 7:00:00 PM)
0.39
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength19.69
Industry Growth24.63
Earnings (Last)02-26 2026-02-26
Earnings (Next)05-26 2026-05-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap40.36M
Revenue(TTM)706.00K
Net Income(TTM)-16.19M
Analysts80
Price Target1.02 (161.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 57.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.01
BVpS-0.2
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.51% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 107.51% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 36.03% | ||
| Cap/Sales | 40.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | -29.67 |
F-Score1
WACC7.98%
ROIC/WACCN/A
Cap/Depr(3y)85.27%
Cap/Depr(5y)122.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.93%
EPS Next Y50%
EPS Next 2Y25.5%
EPS Next 3Y17.86%
EPS Next 5Y17.03%
Revenue 1Y (TTM)-91.82%
Revenue growth 3Y-30.88%
Revenue growth 5YN/A
Sales Q2Q%-97.48%
Revenue Next Year-34.34%
Revenue Next 2Y17.31%
Revenue Next 3Y44.8%
Revenue Next 5Y60.4%
EBIT growth 1Y-322.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-154.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-154.87%
OCF growth 3YN/A
OCF growth 5YN/A
CONAVI MEDICAL CORP / CNVI.CA Fundamental Analysis FAQ
What is the fundamental rating for CNVI stock?
ChartMill assigns a fundamental rating of 1 / 10 to CNVI.CA.
What is the valuation status of CONAVI MEDICAL CORP (CNVI.CA) stock?
ChartMill assigns a valuation rating of 0 / 10 to CONAVI MEDICAL CORP (CNVI.CA). This can be considered as Overvalued.
Can you provide the profitability details for CONAVI MEDICAL CORP?
CONAVI MEDICAL CORP (CNVI.CA) has a profitability rating of 1 / 10.
Can you provide the financial health for CNVI stock?
The financial health rating of CONAVI MEDICAL CORP (CNVI.CA) is 1 / 10.